AZN

AstraZeneca starts trial of antibody treatment for COVID-19

Credit: REUTERS/Brendan McDermid

AstraZeneca said on Tuesday it started early stage trials for an antibody-based treatment for the prevention and treatment of COVID-19, as the British drugmaker also ploughs on with its vaccine candidate.

Aug 25 (Reuters) - AstraZeneca AZN.L said on Tuesday it started early stage trials for an antibody-based treatment for the prevention and treatment of COVID-19, as the British drugmaker also ploughs on with its vaccine candidate.

The trial will evaluate if AZD7442, a combination of two monoclonal antibodies, is safe and tolerable in up to 48 healthy participants between the ages of 18 and 55 years in the United Kingdom with the backing of the United States.

(Reporting by Pushkala Aripaka in Bengaluru; Editing by Shailesh Kuber)

((Pushkala.A@thomsonreuters.com; Twitter: @pullthekart; within UK: +44 20 7542 1810, outside UK: +91 80 6182 2600; Mobile: +91 852 751 3793 ;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

AZN

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More